TRANEXAMIC ACID (tranexamic acid) by Molecular Devices is derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. Approved for hemophilia for short-term use (2 to 8 days) to reduce, prevent hemorrhage, reduce the need for replacement therapy during and 1 more indications. First approved in 2017.
Drug data last refreshed 18h ago
derivative, which diminishes the dissolution of hemostatic fibrin by plasmin. In the presence of tranexamic acid, the lysine receptor binding sites of plasmin for fibrin are occupied, preventing binding to fibrin monomers, thus preserving and stabilizing fibrin's matrix structure. The…
Antifibrinolytic Agent
Worked on TRANEXAMIC ACID at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Efficacy and Safety of Tranexamic Acid in Adult Liver Transplantation---ESTA Trial
Tranexamic Acid for Reduction of Transfusion in Abdominal Surgery
Tranexamic Acid to Reduce Contraceptive-related Bleeding Side Effects
Tranexamic Acid to Reduce Blood Loss in Women Having Planned Cesarean Section
Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women With Placenta Previa